GenCore version 4.5

OM nucleic - nucleic search, using sw model

Run on: September 21, 2002, 21:58:01 ; Search time 214.48 Seconds
(without alignments)
1801.127 Million cell updates/sec

Title: US-09-765-231A-58
Perfect score: 225
Sequence: 1 tgatggtaagttgtttcagg.....attaggaatttttttttttt 225

Scoring table: OLIGO_NUC
Gapop 60.0 , Gapext 60.0

Searched: 1736436 seqs, 858457221 residues

Word size : 0

Total number of hits satisfying chosen parameters: 3472872

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Listing first 45 summaries

Database : N_Geneseq_032802:*
1: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1980.DAT:*
2: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1981.DAT:*
3: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1982.DAT:*
4: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1983.DAT:*
5: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1984.DAT:*
6: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1985.DAT:*
7: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1986.DAT:*
8: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1987.DAT:*
9: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1988.DAT:*
10: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1989.DAT:*
11: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1990.DAT:*
12: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1991.DAT:*
13: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1992.DAT:*
14: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1993.DAT:*
15: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1994.DAT:*
16: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1995.DAT:*
17: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1996.DAT:*
18: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1997.DAT:*
19: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1998.DAT:*
20: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1999.DAT:*
21: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA2000.DAT:*
22: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA2001A.DAT:*
23: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA2001B.DAT:*
24: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	225	100.0	225	22	AAH23128	Osteoarthritis tis
	2	24	10.7	2490	24	ABA05137	Human clathrin lig
c	3	24	10.7	32249	22	AAL04676	Human reproductive
c	4	23	10.2	411	20	AAV89253	EST clone BP199.
c	5	23	10.2	6079	24	ABL32420	Human immune syste
c	6	23	10.2	10039	24	ABL34042	Human immune syste
c	7	23	10.2	13503	24	ABL34071	Human immune syste
c	8	22	9.8	817	22	AAH04871	Human cDNA clone (
c	9	22	9.8	1669	22	AAH18444	Human cDNA sequenc
c	10	22	9.8	6334	22	AAS46457	Tumour suppressor
c	11	22	9.8	24279	22	AAK74999	Human immune/haema
c	12	22	9.8	24329	22	AAK75000	Human immune/haema
c	13	22	9.8	24329	22	AAK75856	Human immune/haema
c	14	22	9.8	32179	22	ABA17139	Human nervous syst
c	15	22	9.8	37973	24	ABL34196	Human immune syste
c	16	21	9.3	240	22	AAK84803	Human immune/haema
c	17	21	9.3	343	22	AAS38504	Novel human diagno
c	18	21	9.3	353	21	AAC32480	Human secreted pro
c	19	21	9.3	357	22	AAF65231	Novel human polynu
	20	21	9.3	377	18	AAT69543	Murine metastatic
c	21	21	9.3	597	22	ABA62564	Human foetal liver
c	22	21	9.3	597	22	ABA29892	Probe #8358 for ge
c	23	21	9.3	597	22	AAK10920	Human brain expres
c	24	21	9.3	597	22	AAK36777	Human bone marrow
c	25	21	9.3	597	22	AAI17628	Probe #7561 for ge
c	26	21	9.3	597	22	AAI42551	Probe #11237 used
c	27	21	9.3	4368	22	AAH48446	Thiolase protein 1
	28	21	9.3	10079	16	AAQ88057	Human EC-SOD gene.
	29	21	9.3	10079	18	AAT92317	Human EC-SOD gene.
	30	21	9.3	10079	21	AAA28294	Human superoxide d
	31	21	9.3	10102	22	AAK83072	Human immune/haema
	32	21	9.3	15548	24	ABL34154	Human immune syste
	33	21	9.3	27118	22	ABA08223	Human ovarian and
	34	21	9.3	27118	22	AAL07542	Human reproductive
c	35	21	9.3	34269	22	AAK68677	Human immune/haema
c	36	21	9.3	34269	22	AAK85168	Human immune/haema
c	37	20	8.9	149	21	AAZ42320	Human 5' EST isola
	38	20	8.9	300	21	AAA00076	Human colon cancer
c	39	20	8.9	546	22	AAH09788	Human cDNA clone (
c	40	20	8.9	579	22	AAS39851	Genomic sequence #
c	41	20	8.9	579	22	AAK90222	Human digestive sy
	42	20	8.9	588	22	AAK85053	Human immune/haema
c	43	20	8.9	717	22	AAF22857	Human prostate can
	44	20	8.9	735	21	AAA02259	Human colon cancer
	45	20	8.9	767	22	AAH04277	Human cDNA clone (

ALIGNMENTS

RESULT 1
AAH23128
ID AAH23128 standard; DNA; 225 BP.
XX
AC AAH23128;
XX
DT 17-SEP-2001 (first entry)
XX
DE Osteoarthritis tissue-derived nucleic acid sequence #58.
XX
KW Osteoarthritis; infectious disorder; Crohn's disease; sepsis; human;
KW wound healing; osteopathic; anti-arthritic, anti-inflammatory;
KW vulnerary; antibacterial; antiallergic; ds.
XX
OS Homo sapiens.
XX
PN WO200153531-A2.
XX
PD 26-JUL-2001.
XX
PF 18-JAN-2001; 2001WO-US00016.
XX
PR 18-JAN-2000; 2000US-0176523.
XX
PA (PHAA) PHARMACIA CORP.
XX
PI Phippard D, Vasanthakamur G, Dotson S, Ma X;
XX
DR WPI; 2001-451914/48.
XX
PT Substantially purified protein, polypeptide or their fragments, used to
PT identify a biologically active compound or composition and treat

PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-465570/50.
XX
PT Isolated nucleic acid molecule encoding a reproductive system antigen
PT is used in preventing, treating or ameliorating a medical condition -
XX
PS Disclosure; SEQ ID NO 7364; 1297pp + Sequence Listing; English.
XX
CC The present invention provides the protein and coding sequences of a
CC number of human reproductive system related antigens. These can be used
CC in the prevention and treatment of reproductive system disorders,
CC including cancer. The present sequence is a genomic sequence encoding a
CC protein of the invention.
XX
SQ Sequence 32249 BP; 7986 A; 7715 C; 7793 G; 8755 T; 0 other;

Query Match 10.7%; Score 24; DB 22; Length 32249;
Best Local Similarity 100.0%; Pred. No. 0.17;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 126 caaaaaacgaaacaaaacaaaaaa 149
||||||||||||||||||||||||
Db 26215 CAAAAAACGAAACAAAACAAAAAA 26192

RESULT 4
AAV89253/c
ID AAV89253 standard; cDNA; 411 BP.

XX
AC AAV89253;
XX
DT 15-FEB-1999 (first entry)
XX
DE EST clone BP199.
XX
KW Human; secreted protein; expressed sequence tag; EST; haematopoiesis;
KW tissue growth; activin; inhibin; chemotaxis; chemokinesis; haemostatic;
KW receptor; ligand; thrombolytic; anti-inflammatory; cadherin; anti-tumour;
KW gene therapy; ss.
XX
OS Homo sapiens.
XX
PN WO9845436-A2.
XX
PD 15-OCT-1998.
XX
PF 10-APR-1998; 98WO-US06955.
XX
PR 10-APR-1997; 97US-0838821.
XX
PA (GEMY) GENETICS INST INC.
XX
PI Agostino MJ, Jacobs K, Lavallie ER, McCoy JM, Merberg D;
PI Racie LA, Spaulding V, Treacy M;
XX
DR WPI; 1999-070077/06.
XX
PT New polynucleotides encoding human secreted proteins - derived from
PT e.g. human blood, kidney, foetal lung, placenta, testes, brain,
PT ovary, pituitary, retina and colon cDNA libraries.
XX
PS Claim 1; Page 158; 618pp; English.
XX
CC The present sequence represents a human expressed sequence tag (EST).
CC The polynucleotide, which is a secreted EST, and the encoded protein
CC are predicted to have useful biological activities which would make
CC them suitable for treating, preventing or ameliorating medical
CC conditions in humans and animals, although no supporting data is
CC given. Suggested activities include nutritional activity, immune
CC stimulating or suppressing activity, haematopoiesis regulating
CC activity, tissue growth activity, activin/inhibin activity,
CC chemotactic/chemokinetic activity, haemostatic and thrombolytic
CC activity, receptor/ligand activity, anti-inflammatory activity,
CC cadherin/tumour invasion suppressor activity, tumour inhibition
CC activity. The polynucleotide may also be useful for gene therapy.
XX
SQ Sequence 411 BP; 125 A; 64 C; 109 G; 113 T; 0 other;

Query Match 10.2%; Score 23; DB 20; Length 411;
Best Local Similarity 100.0%; Pred. No. 0.58;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 127 aaaaaacgaaacaaaacaaaaaa 149
||||||||||||||||||||||
Db 389 AAAAAACGAAACAAAACAAAAA 367

RESULT 5
ABL32420/c
ID ABL32420 standard; DNA; 6079 BP.
XX
AC ABL32420;
XX
DT 26-MAR-2002 (first entry)
XX
DE Human immune system associated gene SEQ ID NO: 393.
XX
KW Human; immune system disease; cytosine methylation; antiasthmatic;
KW antiarteriosclerotic; antianaemic; cytostatic; nootropic;
KW neuroprotective; anti-HIV; anticonvulsant; ophthalmological;
KW antirheumatic; antiarthritic; antidiabetic; antipsoriatic;
KW antiinflammatory; cancer; eye disease; arteriosclerosis; anaemia;
KW acute myeloid leukaemia; Alzheimer's disease; AIDS; epilepsy;
KW neurofibromatosis; rheumatoid arthritis; psoriasis; bowel disease;
KW gene; ds.
XX
OS Homo sapiens.
XX
PN WO200200928-A2.
XX
PD 03-JAN-2002.
XX
PF 02-JUL-2001; 2001WO-EP07537.
XX
PR 30-JUN-2000; 2000DE-1032529.
PR 01-SEP-2000; 2000DE-1043826.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2002-130909/17.
XX
PT Nucleic acid comprising fragment of chemically modified gene, useful
PT for diagnosis and treatment of diseases associated with abnormal
PT cytosine methylation
XX
PS Claim 1; SEQ ID NO 393; 32pp + Sequence Listing; German.
XX
CC The present invention provides a number of human immune system associated
CC genes which are modified by the methylation of cytosines. The sequences
CC can be used in the diagnosis and treatment of immune system disorders,
CC including eye diseases such as retinopathy, neovascular glaucoma and
CC macular degeneration, arteriosclerosis, anaemia, cancer, acute myeloid
CC leukaemia, Alzheimer's disease, AIDS, epilepsy, neurofibromatosis,
CC rheumatoid arthritis, psoriasis and inflammatory/ulcerative bowel
CC diseases. The present sequence is a gene of the invention.
XX
SQ Sequence 6079 BP; 1964 A; 94 C; 1241 G; 2780 T; 0 other;

Query Match 10.2%; Score 23; DB 24; Length 6079;
Best Local Similarity 100.0%; Pred. No. 0.51;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 129 aaaacgaaacaaaacaaaaaaac 151
||||||||||||||||||||||
Db 823 AAAACGAAACAAAACAAAAAAAC 801

RESULT 6
ABL34042/c
ID ABL34042 standard; DNA; 10039 BP.
XX
AC ABL34042;
XX
DT 26-MAR-2002 (first entry)
XX
DE Human immune system associated gene SEQ ID NO: 2015.
XX
KW Human; immune system disease; cytosine methylation; antiasthmatic;
KW antiarteriosclerotic; antianaemic; cytostatic; nootropic;
KW neuroprotective; anti-HIV; anticonvulsant; ophthalmological;
KW antirheumatic; antiarthritic; antidiabetic; antipsoriatic;
KW antiinflammatory; cancer; eye disease; arteriosclerosis; anaemia;
KW acute myeloid leukaemia; Alzheimer's disease; AIDS; epilepsy;
KW neurofibromatosis; rheumatoid arthritis; psoriasis; bowel disease;
KW gene; ds.
XX
OS Homo sapiens.
XX
PN WO200200928-A2.
XX

ID AAC32480 standard; cDNA; 353 BP.
XX
AC AAC32480;
XX
DT 06-OCT-2000 (first entry)
XX
DE Human secreted protein 5' EST, SEQ ID NO: 36555.
XX
KW Human; 5' EST; expressed sequence tag; secreted protein; cDNA isolation;
KW gene therapy; chromosome mapping; ss.
XX
OS Homo sapiens.
XX
PN EP1033401-A2.
XX
PD 06-SEP-2000.
XX
PF 21-FEB-2000; 2000EP-0200610.
XX
PR 26-FEB-1999; 99US-0122487.
XX
PA (GEST) GENSET.
XX
PI Dumas Milne Edwards J, Duclert A, Giordano J;
XX
DR WPI; 2000-500381/45.
XX
PT New nucleic acid that is a 5' expressed sequence tag (5' EST) for
PT obtaining cDNAs and genomic DNAs that correspond to 5'ESTs and for
PT diagnostic, forensic, gene therapy and chromosome mapping procedures -
XX
PS Claim 1; SEQ ID 36555; 71pp + CD-ROM; English.
XX
CC The present sequence is one of a large number of 5' ESTs derived from
CC mRNAs encoding secreted proteins. No ORF has yet been conclusively
CC identified within the present sequence. The 5' ESTs were prepared from
CC total human RNAs or polyA+ RNAs derived from 30 different tissues. EST
CC sequences usually correspond mainly to the 3' untranslated region (UTR)
CC of the mRNA because they are often obtained from oligo-dT primed cDNA
CC libraries. Such ESTs are not well suited for isolating cDNA sequences
CC derived from the 5' ends of mRNAs and even in those cases where longer
CC cDNA sequences have been obtained, the full 5' UTR is rarely included.
CC 5' ESTs are derived from mRNAs with intact 5' ends and can therefore be
CC used to obtain full length cDNAs and genomic DNAs. 5' ESTs are also used
CC in diagnostic, forensic, gene therapy and chromosome mapping procedures.
CC They are used to obtain upstream regulatory sequences and to design
CC expression and secretion vectors.
XX
SQ Sequence 353 BP; 88 A; 80 C; 78 G; 107 T; 0 other;

Query Match 9.3%; Score 21; DB 21; Length 353;
Best Local Similarity 100.0%; Pred. No. 4.6;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 129 aaaacgaaacaaaacaaaaaa 149
||||||||||||||||||||
Db 267 AAAACGAAACAAAACAAAAAA 247

RESULT 19
AAF65231/c
ID AAF65231 standard; cDNA; 357 BP.
XX
AC AAF65231;
XX
DT 09-APR-2001 (first entry)
XX
DE Novel human polynucleotide, SEQ ID NO: 987.
XX
KW Human; cytostatic; gene therapy; colon cancer; prostate cancer;
KW breast cancer; lung cancer; cancer detection; ss.
XX
OS Homo sapiens.
XX
PN WO200102568-A2.
XX
PD 11-JAN-2001.
XX
PF 30-JUN-2000; 2000WO-US18374.
XX
PR 02-JUL-1999; 99US-0142310.
PR 02-JUL-1999; 99US-0142311.
XX
PA (CHIR) CHIRON CORP.
PA (HYSE-) HYSEQ INC.
XX
PI Williams LT, Escobedo J, Innis MA, Garcia PD, Klinger J, Kassam A;
PI Reinhard C, Randazzo F, Kennedy GC, Pot D, Lamson G, Drmanac R;
PI Crkenjakov R, Drmanac S, Dickson M, Labat I, Leshkowitiz D;
PI Kita D, Garcia V, Jones LW, Strache-Crain B;
XX
DR WPI; 2001-091805/10.
XX
PT Library of polynucleotides for diagnosing a cancerous state of a
PT mammalian cell and detecting cancer, particularly of the colon or
PT prostate, comprises 3351 human polynucleotide sequences -
XX
PS Claim 9; Page 685; 1046pp; English.
XX
CC The present sequence is one of 3351 sequences in a library of human
CC polynucleotides. The library is used to detect differentially expressed
CC genes correlated with a cancerous state of a mammalian cell and can
CC detect colon, prostate, breast and lung cancer. The library can be used
CC to produce probes for detection of mRNA and to produce additional copies
CC of the polynucleotides. The probes can be used for chromosome mapping of
CC the polynucleotide and for detection of transcription levels. Ribozymes
CC or antisense oligonucleotides can be generated. The polynucleotides and
CC their gene products are used as genetic or biochemical markers (e.g. in
CC blood or tissues) that will detect the earliest changes along the
CC carcinogenesis pathway and/or monitor the efficacy of therapies and
CC preventive interventions. The polynucleotides, polypeptides and
CC antibodies against them can be used in pharmaceutical compositions to
CC treat the cancers and proliferative disorders such as neoplasia,
CC dysplasia and hyperplasia.
XX
SQ Sequence 357 BP; 87 A; 63 C; 75 G; 131 T; 1 other;

Query Match 9.3%; Score 21; DB 22; Length 357;
Best Local Similarity 100.0%; Pred. No. 4.6;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 127 aaaaaacgaaacaaaacaaaa 147
|||||||||||||||||||||
Db 248 AAAAAACGAAACAAAACAAAA 228

RESULT 20
AAT69543
ID AAT69543 standard; cDNA; 377 BP.
XX
AC AAT69543;
XX
DT 26-FEB-1998 (first entry)
XX
DE Murine metastatic nucleic acid sequence.
XX
KW Mouse; murine; tumour; cancer; metastatic sequence; detection;
KW diagnosis; treatment; metastasis; hyperplasia; dysplasia;
KW hypertrophy; screening; ss.
XX
OS Mus musculus.
XX
PN WO9718454-A2.
XX

PD 22-MAY-1997.
XX
PF 15-NOV-1996; 96WO-US18567.
XX
PR 30-JAN-1996; 96US-0594031.
PR 16-NOV-1995; 95US-0006838.
XX
PA (THOM/) THOMPSON T.
XX
PI Thompson T;
XX
DR WPI; 1997-289397/26.
XX
PT Identifying tumour metastatic sequences - by introducing transfected
PT cells into host mammal and analysing primary and metastatic
PT sequences by differential display PCR
XX
PS Disclosure; Fig 12FL; 102pp; English.
XX
CC Mouse Urogenital Sinus (UGS) tissue was isolated from 17 day old
CC mouse embryos. The UGS cells were infected with retroviruses,
CC cultured and implanted under the renal capsule of mice.
CC Reconstitutions were harvested 5 weeks later, when they showed
CC signs of distress from the tumour burden. Metastasised tumours were
CC isolated from a site outside the renal capsule. RNA was isolated
CC from primary tumours and metastases, reverse transcribed and
CC subjected to differential display PCR. The sequences were analysed
CC to obtain metastatic sequences, e.g. the present sequence. The
CC method can be used to detect, diagnose and treat disorders related
CC to metastasis, or treat malignant or non-malignant disorders, e.g.
CC hyperplasia, dysplasia and hypertrophy. The metastatic sequence can
CC be used to screen a biological sample for metastasis, and it or its
CC expression product may also be used to treat a metastatic disorder.
XX
SQ Sequence 377 BP; 110 A; 66 C; 107 G; 94 T; 0 other;

Query Match 9.3%; Score 21; DB 18; Length 377;
Best Local Similarity 100.0%; Pred. No. 4.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 128 aaaaacgaaacaaaacaaaaa 148
||||||||||||||||||||
Db 18 aaaaacgaaacaaaacaaaaa 38

RESULT 21
ABA62564/c
ID ABA62564 standard; DNA; 597 BP.
XX
AC ABA62564;
XX
DT 01-FEB-2002 (first entry)
XX
DE Human foetal liver single exon nucleic acid probe #10869.
XX
KW Human; foetal liver; gene expression; single exon nucleic acid probe; ss.
XX
OS Homo sapiens.
XX
PN WO200157277-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US00669.
XX
PR 04-FEB-2000; 2000US-0180312.
PR 26-MAY-2000; 2000US-0207456.
PR 30-JUN-2000; 2000US-0608408.
PR 03-AUG-2000; 2000US-0632366.
PR 21-SEP-2000; 2000US-0234687.
PR [illegible]-SEP-2000; 2000US-0236359.
PR [illegible]000; 2000GB-0024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-483447/52.
XX
PT Human genome-derived single exon nucleic acid probes useful for
PT analyzing gene expression in human fetal liver -
XX
PS Claim 1; SEQ ID NO 10869; 639pp + sequence listing; English.
XX
CC The invention relates to a single exon nucleic acid probe for
CC measuring human gene expression in a sample derived from human foetal
CC liver. The single exon nucleic acid probes may be used for predicting,
CC measuring and displaying gene expression in samples derived from human
CC fetal liver. The present sequence is a single exon nucleic acid
CC probe of the invention.
CC Note: The sequence data for this patent did not form part of the
CC printed specification, but was obtained in electronic format directly
CC from WIPO at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 597 BP; 228 A; 67 C; 170 G; 132 T; 0 other;

Query Match 9.3%; Score 21; DB 22; Length 597;
Best Local Similarity 100.0%; Pred. No. 4.4;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 127 aaaaaacgaaacaaaacaaaa 147
|||||||||||||||||||||
Db 252 AAAAAACGAAACAAAACAAAA 232

RESULT 22
ABA29892/c
ID ABA29892 standard; DNA; 597 BP.
XX
AC ABA29892;
XX
DT 23-JAN-2002 (first entry)
XX
DE Probe #8358 for gene expression analysis in human heart cell sample.
XX
KW Human; gene expression; heart; microarray; vascular system; probe;
KW cardiovascular disease; hypertension; cardiac arrhythmia;
KW congenital heart disease; ss.
XX
OS Homo sapiens.
XX
PN WO200157274-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US00666.
XX
PR 04-FEB-2000; 2000US-0180312.
PR 26-MAY-2000; 2000US-0207456.
PR 30-JUN-2000; 2000US-0608408.
PR 03-AUG-2000; 2000US-0632366.
PR 21-SEP-2000; 2000US-0234687.
PR 27-SEP-2000; 2000US-0236359.
PR 04-OCT-2000; 2000GB-0024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488899/53.
XX
PT Single exon nucleic acid probes for analyzing gene expression in human
PT hearts -
XX

GenCore version 4.5

OM nucleic - nucleic search, using sw model

Run on: September 21, 2002, 19:50:25 ; Search time 46.51 Seconds
(without alignments)
1188.294 Million cell updates/sec

Title: US-09-765-231A-58
Perfect score: 225
Sequence: 1 tgatggtaagttgtttcagg.....attaggaatttttttttttt 225

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 383533 seqs, 122816752 residues

Total number of hits satisfying chosen parameters: 767066

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued_Patents_NA:*
1: /cgn2_6/ptodata/1/ina/5A_COMB.seq:*
2: /cgn2_6/ptodata/1/ina/5B_COMB.seq:*
3: /cgn2_6/ptodata/1/ina/6A_COMB.seq:*
4: /cgn2_6/ptodata/1/ina/6B_COMB.seq:*
5: /cgn2_6/ptodata/1/ina/PCTUS_COMB.seq:*
6: /cgn2_6/ptodata/1/ina/backfiles1.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	37.6	16.7	5852	1	US-07-867-106-2	Sequence 2, Appli
c	2	37.4	16.6	2268	2	US-08-873-093-2	Sequence 2, Appli
	3	33	14.7	2107	4	US-09-180-852-1	Sequence 1, Appli
	4	33	14.7	7210	2	US-08-257-963B-10	Sequence 10, Appl
	5	33	14.7	7210	4	US-08-367-841A-10	Sequence 10, Appl
	6	33	14.7	7210	5	PCT-US95-07201-10	Sequence 10, Appl
	7	33	14.7	22481	4	US-08-367-841A-43	Sequence 43, Appl
	8	33	14.7	22481	5	PCT-US95-07201-43	Sequence 43, Appl
c	9	32.6	14.5	334	2	US-09-032-684-8	Sequence 8, Appli
	10	32.6	14.5	1894	4	US-09-004-731-29	Sequence 29, Appl
c	11	32.6	14.5	1894	4	US-09-004-731-31	Sequence 31, Appl
	12	32.6	14.5	1894	4	US-09-032-215-3	Sequence 3, Appli
	13	32.6	14.5	1894	4	US-08-749-699-29	Sequence 29, Appl
c	14	32.6	14.5	1894	4	US-08-749-699-31	Sequence 31, Appl
c	15	32.6	14.5	51259	3	US-08-781-891-209	Sequence 209, App
	16	32.2	14.3	2502	3	US-09-234-332-1	Sequence 1, Appli
	17	32	14.2	6769	1	US-08-480-784-20	Sequence 20, Appl
	18	32	14.2	6769	1	US-08-483-553-20	Sequence 20, Appl
	19	32	14.2	6769	1	US-08-487-002-20	Sequence 20, Appl
	20	32	14.2	6769	1	US-08-483-554B-20	Sequence 20, Appl
	21	32	14.2	6769	1	US-08-488-011B-20	Sequence 20, Appl
	22	32	14.2	6769	4	US-08-850-727-20	Sequence 20, Appl
	23	32	14.2	6769	5	PCT-US95-10202-20	Sequence 20, Appl
	24	32	14.2	6769	5	PCT-US95-10203-20	Sequence 20, Appl
	25	32	14.2	6769	5	PCT-US95-10220-20	Sequence 20, Appl
c	26	31.8	14.1	152331	3	US-09-128-155-16	Sequence 16, Appl
	27	31.8	14.1	176373	3	US-09-128-155-17	Sequence 17, Appl
	28	31.6	14.0	4673	1	US-07-638-431-1	Sequence 1, Appli
	29	31.6	14.0	4673	5	PCT-US92-00018-1	Sequence 1, Appli
c	30	31.2	13.9	1330	4	US-09-118-442-29	Sequence 29, Appl
c	31	31.2	13.9	1330	4	US-09-677-064-29	Sequence 29, Appl
	32	31.2	13.9	3095	6	5231168-1	Patent No. 5231168
c	33	31	13.8	624	4	US-09-397-992A-3	Sequence 3, Appli
c	34	31	13.8	624	4	US-09-397-992A-6	Sequence 6, Appli
c	35	31	13.8	4106	2	US-08-702-572-14	Sequence 14, Appl
c	36	31	13.8	4732	6	5521093-4	Patent No. 5521093
c	37	30.8	13.7	4411529	4	US-09-103-840A-1	Sequence 1, Appli
c	38	30.6	13.6	90050	4	US-09-245-041-5	Sequence 5, Appli
c	39	30.4	13.5	260	4	US-08-134-198E-11	Sequence 11, Appl
	40	30.4	13.5	7208	3	US-09-166-186-107	Sequence 107, App
	41	30.4	13.5	7208	4	US-09-313-932-107	Sequence 107, App
c	42	30.4	13.5	37950	4	US-09-338-907-183	Sequence 183, App
c	43	30.4	13.5	37950	4	US-09-218-207-183	Sequence 183, App
	44	30.2	13.4	838	3	US-09-054-368-9	Sequence 9, Appli
	45	30.2	13.4	838	3	US-09-054-274-9	Sequence 9, Appli

ALIGNMENTS

```
RESULT 1
US-07-867-106-2
; Sequence 2, Application US/07867106
; Patent No. 5389526
; GENERAL INFORMATION:
;   APPLICANT: Slade, Martin B
;   APPLICANT: Chang, Andy C M
;   APPLICANT: Williams, Keith L
;   TITLE OF INVENTION: Improved Plasmid Vectors for Cellular
;   TITLE OF INVENTION: Slime Moulds of the Genus Dictyostelium
;   NUMBER OF SEQUENCES: 19
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 5389526ris
;     STREET: One Liberty Place 46th Floor
;     CITY: Philadelphia
;     STATE: PA
;     COUNTRY: USA
;     ZIP: 19103
;   COMPUTER READABLE FORM:
;     MEDIUM TYPE: Floppy disk
;     COMPUTER: IBM PC compatible
;     OPERATING SYSTEM: PC-DOS/MS-DOS
;     SOFTWARE: PatentIn Release #1.0, Version #1.25
;   CURRENT APPLICATION DATA:
;     APPLICATION NUMBER: US/07/867,106
;     FILING DATE: 19920625
;   PRIOR APPLICATION DATA:
;     APPLICATION NUMBER: AU PJ 7187
;     APPLICATION NUMBER: PCT/AU90/00530
;     FILING DATE: 02-NOV-1989
;   ATTORNEY/AGENT INFORMATION:
;     NAME: Feeney, Joanne Longo
;     REGISTRATION NUMBER: 35,134
;     REFERENCE/DOCKET NUMBER: RICE-0002
;   TELECOMMUNICATION INFORMATION:
;     TELEPHONE: 215-568-3100
;     TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 2:
;   SEQUENCE CHARACTERISTICS:
;     LENGTH: 5852 base pairs
;     TYPE: NUCLEIC ACID
;     STRANDEDNESS: single
;     TOPOLOGY: linear
;   MOLECULE TYPE: DNA (genomic)
;   ANTI-SENSE: NO
;   FEATURE:
;     NAME/KEY: CDS
;     LOCATION: 2378..5038
;   FEATURE:
;     NAME/KEY: CDS
```

; LOCATION: 2378..5038
US-07-867-106-2

Query Match 16.7%; Score 37.6; DB 1; Length 5852;
Best Local Similarity 48.6%; Pred. No. 0.37;
Matches 103; Conservative 0; Mismatches 109; Indels 0; Gaps 0;

Qy 14 tttcaggcataaaatttgaaataaattatgaggctccatgatatgctatattggttttac 73
Db 1906 TTTAAAATTAAAAGTTATTTTTAAATATGCAAAAACTATAAAAAACTAATGTAGTTTAAC 1965

Qy 74 cttcagaagaatatttagtttcactcaggtttttcaaagctacgctgtcccccaaaaaac 133
Db 1966 CAACTTTTTTCTATTTCTTTTTTTTTTTTTTTTTTTTTTTACTTTGAAAAAAAAAAAAA 2025

Qy 134 gaaacaaaacaaaaaaacaacctttttaagagttgatggctactcatttgatctgcctcc 193
Db 2026 AAAAAAAAAAAAAAAAAACCCTCATTATAAATATTAATTACTTTGGTTTTTTTTGATTTT 2085

Qy 194 tctgctgaatcaattaggaatttttttttttt 225
Db 2086 TTTTTTAATAAATTTAAAATTTTATTCTCTAT 2117

RESULT 2
US-08-873-093-2/c
; Sequence 2, Application US/08873093
; Patent No. 5853997
; GENERAL INFORMATION:
; APPLICANT: Bandman, Olga
; APPLICANT: Goli, Surya K.
; APPLICANT: Lal, Preeti
; APPLICANT: Corley, Neil C.
; APPLICANT: Zhang, Hong
; TITLE OF INVENTION: NEW PROTEIN PHOSPHATASE
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Incyte Pharmaceuticals, Inc.
; STREET: 3174 Porter Drive
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94304
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/873,093
; FILING DATE: Filed Herewith
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Billings, Lucy J.
; REGISTRATION NUMBER: 36,749
; REFERENCE/DOCKET NUMBER: PF-0319 US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-855-0555
; TELEFAX: 415-845-4166
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 2268 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; LIBRARY: 13177
; CLONE: THPIPLB01
; 873-093-2

Query Match 16.6%; Score 37.4; DB 2; Length 2268;
Best Local Similarity 53.0%; Pred. No. 0.35;
Matches 80; Conservative 0; Mismatches 71; Indels 0; Gaps 0;

Qy 29 ttgaaataaattatgaggctccatgatatgctatattggttttaccttcagaagaatatt 88
Db 2195 TTGACATACATTTTGATGTGTGTAGTTAGGCTATACAGAATATACAAACCAAAGCTGTAT 2136

Qy 89 tagtttcactcaggtttttcaaagctacgctgtcccccaaaaaacgaaacaaaacaaaaa 148
Db 2135 GAATAATACATAGGTTTTTCAAAAGTTATGTTTCATAAAGAATACAGAGAAAGGAAAAAT 2076

Qy 149 aacaaccttttttaagagttgatggctactca 179
Db 2075 AGCCACACATCCAATATCTCACAACTTCTAA 2045

RESULT 3
US-09-180-852-1
; Sequence 1, Application US/09180852
; Patent No. 6287834
; GENERAL INFORMATION:
; APPLICANT: BELANGER, Alain
; APPLICANT: HUM, Dean W.
; APPLICANT: BEAULIEU, Martin
; APPLICANT: LEVESQUE, Eric
; TITLE OF INVENTION: CHARACTERIZATION AND USE OF AN ISOLATED URIDINE
; TITLE OF INVENTION: DIPHOSPHO-GLUCURONOSYLTRANSFERASE
; FILE REFERENCE: 1259-449
; CURRENT APPLICATION NUMBER: US/09/180,852
; CURRENT FILING DATE: 1999-02-08
; EARLIER APPLICATION NUMBER: PCT/CA97/00328
; EARLIER FILING DATE: 1997-05-16
; EARLIER APPLICATION NUMBER: US 08/649,319
; EARLIER FILING DATE: 1996-05-17
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1
; LENGTH: 2107
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (52)..(1644)
US-09-180-852-1

Query Match 14.7%; Score 33; DB 4; Length 2107;
Best Local Similarity 60.7%; Pred. No. 4.4;
Matches 54; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 60 tatattggttttaccttcagaagaatatttagtttcactcaggtttttcaaagctacgct 119
Db 2019 tattttggcttcattttgagcagaatttttgttttttaattttgccaatgaaatcttcaat 2078

Qy 120 gtccccccaaaaaacgaaacaaaacaaaaa 148
Db 2079 aattaaaaaaaaaaaaaaaaaaaaaaaaa 2107

RESULT 4
US-08-257-963B-10
; Sequence 10, Application US/08257963B
; Patent No. 5840686
; GENERAL INFORMATION:
; APPLICANT: Chader, Gerald J.; Becerra, S.
; APPLICANT: Patricia; Schwartz, Joan P.;
; APPLICANT: Taniwaki, Takayuki
; TITLE OF INVENTION: PIGMENT EPITHELIUM
; TITLE OF INVENTION: DERIVED FACTOR: CHARACTERIZATION OF ITS NOVEL
; TITLE OF INVENTION: BIOLOGICAL ACTIVITY AND SEQUENCES ENCODING
; TITLE OF INVENTION: AND EXPRESSING THE PROTEIN